Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 44.66
(-3.17%)
CNY 44.66
(-3.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.85 Billion CNY | 11.59% |
| 2022 | 2.56 Billion CNY | 39.94% |
| 2021 | 1.82 Billion CNY | 17.89% |
| 2020 | 1.55 Billion CNY | -4.34% |
| 2019 | 1.62 Billion CNY | 134.88% |
| 2018 | 690.68 Million CNY | 38.74% |
| 2017 | 497.84 Million CNY | 182.04% |
| 2016 | 176.51 Million CNY | -22.24% |
| 2015 | 227.01 Million CNY | 50.26% |
| 2014 | 151.08 Million CNY | 115.85% |
| 2013 | 69.99 Million CNY | 50.82% |
| 2012 | 46.41 Million CNY | 17.92% |
| 2011 | 39.35 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.58 Billion CNY | -6.22% |
| 2024 Q1 | 2.75 Billion CNY | -3.66% |
| 2024 Q3 | 2.9 Billion CNY | 12.49% |
| 2023 Q3 | 2.71 Billion CNY | 5.11% |
| 2023 Q4 | 2.85 Billion CNY | 5.25% |
| 2023 FY | 2.85 Billion CNY | 11.59% |
| 2023 Q1 | 2.35 Billion CNY | -8.09% |
| 2023 Q2 | 2.58 Billion CNY | 9.74% |
| 2022 Q4 | 2.56 Billion CNY | -0.46% |
| 2022 Q3 | 2.57 Billion CNY | 11.22% |
| 2022 Q2 | 2.31 Billion CNY | 12.78% |
| 2022 FY | 2.56 Billion CNY | 39.94% |
| 2022 Q1 | 2.05 Billion CNY | 12.07% |
| 2021 Q1 | 1.32 Billion CNY | -14.49% |
| 2021 Q3 | 1.68 Billion CNY | 4.24% |
| 2021 Q4 | 1.82 Billion CNY | 8.64% |
| 2021 FY | 1.82 Billion CNY | 17.89% |
| 2021 Q2 | 1.61 Billion CNY | 21.76% |
| 2020 Q2 | 1.78 Billion CNY | 19.19% |
| 2020 Q3 | 1.85 Billion CNY | 4.36% |
| 2020 FY | 1.55 Billion CNY | -4.34% |
| 2020 Q4 | 1.55 Billion CNY | -16.53% |
| 2020 Q1 | 1.49 Billion CNY | -7.86% |
| 2019 Q4 | 1.62 Billion CNY | 10.42% |
| 2019 FY | 1.62 Billion CNY | 134.88% |
| 2019 Q3 | 1.46 Billion CNY | 53.79% |
| 2019 Q2 | 955.33 Million CNY | 25.93% |
| 2019 Q1 | 758.59 Million CNY | 9.83% |
| 2018 Q2 | 608.64 Million CNY | 13.82% |
| 2018 Q4 | 690.68 Million CNY | 9.24% |
| 2018 FY | 690.68 Million CNY | 38.74% |
| 2018 Q3 | 632.24 Million CNY | 3.88% |
| 2018 Q1 | 534.73 Million CNY | 7.41% |
| 2017 Q2 | 415.63 Million CNY | -14.49% |
| 2017 Q1 | 486.09 Million CNY | 175.38% |
| 2017 Q3 | 466.34 Million CNY | 12.2% |
| 2017 Q4 | 497.84 Million CNY | 6.75% |
| 2017 FY | 497.84 Million CNY | 182.04% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q3 | 164.14 Million CNY | -35.31% |
| 2016 Q4 | 176.51 Million CNY | 7.54% |
| 2016 FY | 176.51 Million CNY | -22.24% |
| 2016 Q2 | 253.74 Million CNY | 0.0% |
| 2015 Q1 | 207.21 Million CNY | 0.0% |
| 2015 FY | 227.01 Million CNY | 50.26% |
| 2015 Q4 | 227.01 Million CNY | 0.0% |
| 2015 Q2 | 207.21 Million CNY | 0.0% |
| 2015 Q3 | - CNY | -100.0% |
| 2014 FY | 151.08 Million CNY | 115.85% |
| 2013 FY | 69.99 Million CNY | 50.82% |
| 2012 FY | 46.41 Million CNY | 17.92% |
| 2011 FY | 39.35 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 8.84 Billion CNY | 67.702% |
| Joinn Laboratories(China)Co.,Ltd. | 1.67 Billion CNY | -70.895% |
| WuXi AppTec Co., Ltd. | 17.66 Billion CNY | 83.831% |
| Thalys Medical Technology Group Inc. | 2.02 Billion CNY | -40.928% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 3.19 Billion CNY | 10.596% |
| Chemclin Diagnostics Co., Ltd. | 431.76 Million CNY | -561.65% |